Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 439

Showing 26-50 of 439 citing articles:

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
Devesh Aggarwal, Jie Yang, Md. Abdus Salam, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma
Junyu Wu, Yau‐Tuen Chan, Yuanjun Lu, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 1946-1973
Open Access | Times Cited: 23
Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines
Anna Hargrave, Abu Salim Mustafa, Asma Hanif, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1633-1633
Open Access | Times Cited: 23
mRNA: A promising platform for cancer immunotherapy
Byoungjae Kong, Yelee Kim, Eun Hye Kim, et al.
Advanced Drug Delivery Reviews (2023) Vol. 199, pp. 114993-114993
Open Access | Times Cited: 22
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Bao-Toan Nguyen Dang, Taeg Kyu Kwon, Sooyeun Lee, et al.
Journal of Controlled Release (2023) Vol. 365, pp. 773-800
Closed Access | Times Cited: 22
A Comprehensive Strategy Based on High Clinical Translational Nanosystem for Programmable Immunotherapy of Triple Negative Breast Cancer
Meng Meng, Jiayan Wu, Yuanji Feng, et al.
Advanced Materials (2024) Vol. 36, Iss. 27
Closed Access | Times Cited: 15
New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3
Ioannis‐Alexios Koumprentziotis, Charalampos Theocharopoulos, Dimitra Foteinou, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 54-54
Open Access | Times Cited: 14
Advancing nanotechnology for neoantigen-based cancer theranostics
Jianhua Zou, Yu Zhang, Yuanbo Pan, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 7, pp. 3224-3252
Open Access | Times Cited: 14
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
Siwei Zheng, Wenwen Wang, Lesang Shen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 13
Vaccine Target Discovery
Li Chuin Chong, Asif Manzoor Khan
Elsevier eBooks (2024)
Closed Access | Times Cited: 12
Immune Cell Migration to Cancer
Allison Ryan, Minsoo Kim, Kihong Lim
Cells (2024) Vol. 13, Iss. 10, pp. 844-844
Open Access | Times Cited: 11
Programmed Lung Metastasis Immunotherapy via Cascade‐Responsive Cell Membrane‐Mimetic Copolymer‐Wrapped Nanoraspberry‐Mediated Elesclomol‐Copper Delivery
Thi My Hue Huynh, Van‐Sieu Luc, Min‐Ren Chiang, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 34
Closed Access | Times Cited: 11
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Zhaokai Zhou, Jiahui Wang, Jiaojiao Wang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Messenger RNA Surveillance: Current Understanding, Regulatory Mechanisms, and Future Implications
Rutupurna Das, G. Panigrahi
Molecular Biotechnology (2024)
Closed Access | Times Cited: 9
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Ankita Mitra, Anoop Kumar, Nitin Amdare, et al.
Biology (2024) Vol. 13, Iss. 5, pp. 307-307
Open Access | Times Cited: 9
State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers
Scott Strum, Mads Hald Andersen, Inge Marie Svane, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 8
The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors
Renhao Li, Jingchu Hu, Rong Li, et al.
Cell Discovery (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer
Yun Qiao, Kaiyuan Hui, Chenxi Hu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access | Times Cited: 1
An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy
Yichao Lu, Nana Ma, Keman Cheng, et al.
Advanced Materials (2025)
Closed Access | Times Cited: 1
Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources
Yunzhe Wang, James Wengler, Yousheng Fang, et al.
Genomics Proteomics & Bioinformatics (2025)
Open Access | Times Cited: 1
Large-scale transcript variants dictate neoepitopes for cancer immunotherapy
Shiliang Ji, Feifan Wang, Yongjie Wu, et al.
Science Advances (2025) Vol. 11, Iss. 5
Open Access | Times Cited: 1
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens
Minghui Chen, Jie Jiang, Hengyu Chen, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010150-e010150
Open Access | Times Cited: 1
Cancer vaccines: current status and future directions
Yi Zhou, Yuquan Wei, Xiaohe Tian, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Therapeutic potential of flavonoids in gastrointestinal cancer: Focus on signaling pathways and improvement strategies (Review)
Ye Ding, Yong Yu
Molecular Medicine Reports (2025) Vol. 31, Iss. 4, pp. 1-34
Closed Access | Times Cited: 1
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
Xingyu Chen, Lixiang Feng, Yujing Huang, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 104-104
Open Access | Times Cited: 37

Scroll to top